Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Patients With Potentially High Recurrence Risk After Liver Cancer Resection: a Prospective, Randomized, Controlled Clinical Study

NCT05250843 is registered in ClinicalTrials.gov with Third Affiliated Hospital, Sun Yat-Sen University as lead sponsor.

NCT NCT05250843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05250843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Patients With Potentially High Recurrence Risk After Liver Cancer Resection: a Prospective, Randomized, Controlled Clinical Study
Lead sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Phase
Phase 2/3
Overall status
Unknown status
Start date
May 30, 2022
Completion date
December 30, 2024
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma